Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease

NCT05006885 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT05006885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease
Lead sponsor
Altimmune, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2021
Completion date
August 17, 2022
Enrollment
95 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease